Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface ("BCI") Technology Private Subsidiary

Core Insights - Helius Medical Technologies, Inc. has established a wholly-owned subsidiary, Revelation Neuro, Inc., to develop non-implantable AI-powered brain-computer interface (BCI) technology aimed at enhancing neurorehabilitation [1][2][3] - The new technology will utilize Helius' existing intellectual property (IP) and a dataset of over 5 years of clinical evidence from more than 400 subjects to optimize therapeutic responses through translingual stimulation [3] - Helius plans to present at the 37th Annual Roth Conference on March 17, 2025, to discuss its advancements and future plans [4] Company Overview - Helius Medical Technologies focuses on neurologic deficits and aims to improve the lives of individuals with neurologic diseases through its innovative neuromodulation technology [5] - The company's first commercial product is the Portable Neuromodulation Stimulator (PoNS®), which enhances the brain's ability to engage compensatory mechanisms and promote neuroplasticity [5] Revelation Neuro's Objectives - Revelation Neuro aims to create a new standard of care for personalized neurorehabilitation by combining newly developed IP with Helius' existing IP [2] - The subsidiary will focus on maximizing the effects of neuromodulation by applying AI to tailor individual responses to treatment [3] - Future applications may extend to addressing neurological conditions such as cognitive deficits and mood disorders [3] Financial Strategy - Helius has invested over $70 million in developing its neuromodulation technology and data collection, which will support the rapid development of Revelation Neuro's AI-powered BCI [3] - The company does not plan to invest significant additional capital into Revelation Neuro but expects it to be financed through third-party sources [3]